Severe acute GvHD following administration of ipilimumab for early relapse of AML after haploidentical stem cell transplantation

Bone Marrow Transplant. 2017 Jul;52(7):1047-1048. doi: 10.1038/bmt.2017.78. Epub 2017 Jun 5.

Authors

F-X Gros¹, T Cazaubiel¹, E Forcade¹, N Lechevalier², T Leguay¹, V Servant³, R Tabrizi¹, L Clement¹, P-Y Dumas¹, A Bidet², A Pigneux¹, S Vigouroux¹, N Milpied¹

Affiliations

¹ Department of Hematology and Cell Therapy, University Hospital, Bordeaux, France.
² Laboratory of Hematology, University Hospital, Bordeaux, France.
³ Department of Pharmacy, University Hospital, Bordeaux, France.

PMID: 28581465
DOI: 10.1038/bmt.2017.78

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Allografts
Graft vs Host Disease* / chemically induced
Graft vs Host Disease* / metabolism
Graft vs Host Disease* / pathology
Humans
Ipilimumab / administration & dosage
Ipilimumab / adverse effects*
Leukemia, Myeloid, Acute / metabolism
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Male
Recurrence
Severity of Illness Index
Stem Cell Transplantation*

Substances

Ipilimumab